These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28277814)

  • 41. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.
    Arce JC; La Marca A; Mirner Klein B; Nyboe Andersen A; Fleming R
    Fertil Steril; 2013 May; 99(6):1644-53. PubMed ID: 23394782
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.
    Wdowiak A; Bojar I
    Reprod Health; 2015 Dec; 12():113. PubMed ID: 26667662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The dynamic changes of anti-Mullerian hormone and inhibin B during controlled ovarian hyperstimulation in decreased ovarian reserve women and the effect on clinical outcome.
    Li Y; Nie M; Liu Y; Zhang W; Yang X
    Gynecol Endocrinol; 2015 Jun; 31(6):450-3. PubMed ID: 25585549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation.
    Cerra C; Newman WG; Tohlob D; Byers H; Horne G; Roberts SA; Mohiyiddeen L
    J Assist Reprod Genet; 2016 Aug; 33(8):1085-91. PubMed ID: 27142041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF.
    Kotanidis L; Nikolettos K; Petousis S; Asimakopoulos B; Chatzimitrou E; Kolios G; Nikolettos N
    J Endocrinol Invest; 2016 Dec; 39(12):1459-1464. PubMed ID: 27465668
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of blood groups with ovarian reserve and outcome of in vitro fertilization treatment.
    Awartani K; Al Ghabshi R; Al Shankiti H; Al Dossari M; Coskun S
    Ann Saudi Med; 2016; 36(2):116-20. PubMed ID: 27031784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization.
    Honnma H; Baba T; Sasaki M; Hashiba Y; Oguri H; Fukunaga T; Endo T; Asada Y
    J Assist Reprod Genet; 2012 Feb; 29(2):117-25. PubMed ID: 22086616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of the lower serum anti-Müllerian hormone threshold for ovarian stimulation prior to in-vitro fertilization using the Elecsys® AMH assay: a prospective observational study.
    Grynnerup AG; Løssl K; Pilsgaard F; Lunding SA; Storgaard M; Bogstad JW; Prætorius L; Zedeler A; Bungum L; Nyboe Andersen A; Pinborg A
    Reprod Biol Endocrinol; 2019 Jan; 17(1):11. PubMed ID: 30634990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Individualization of controlled ovarian stimulation in vitro fertilization using ovarian reserve markers.
    Grisendi V; La Marca A
    Minerva Ginecol; 2017 Jun; 69(3):250-258. PubMed ID: 28271699
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve.
    Di Paola R; Garzon S; Giuliani S; Laganà AS; Noventa M; Parissone F; Zorzi C; Raffaelli R; Ghezzi F; Franchi M; Zaffagnini S
    Arch Gynecol Obstet; 2018 Nov; 298(5):1029-1035. PubMed ID: 30242498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Estimation of ovarian response using multiple predictors of ovarian reserve in women undergoing in vitro fertilization-embryo transfer].
    He Y; Xia R; Chen X; Ye D; Tang Y; Li P; Niu J; Chen S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):216-20. PubMed ID: 23443775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders.
    Yeung TW; Chai J; Li RH; Lee VC; Ho PC; Ng EH
    Fertil Steril; 2014 Jul; 102(1):108-115.e1. PubMed ID: 24796766
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Arce JC; Andersen AN; Fernández-Sánchez M; Visnova H; Bosch E; García-Velasco JA; Barri P; de Sutter P; Klein BM; Fauser BC
    Fertil Steril; 2014 Dec; 102(6):1633-40.e5. PubMed ID: 25256937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF.
    Biasoni V; Patriarca A; Dalmasso P; Bertagna A; Manieri C; Benedetto C; Revelli A
    Reprod Biol Endocrinol; 2011 Aug; 9():112. PubMed ID: 21824441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization.
    Hamdine O; Eijkemans MJC; Lentjes EGW; Torrance HL; Macklon NS; Fauser BCJM; Broekmans FJ
    Fertil Steril; 2015 Oct; 104(4):891-898.e2. PubMed ID: 26196233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interchangeability of two assays for the measurement of anti-Müllerian hormone when personalizing the dose of FSH in
    La Marca A; Tolani AD; Capuzzo M
    Gynecol Endocrinol; 2021 Apr; 37(4):372-376. PubMed ID: 32856971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome.
    Köninger A; Sauter L; Edimiris P; Kasimir-Bauer S; Kimmig R; Strowitzki T; Schmidt B
    Hum Reprod; 2014 Mar; 29(3):518-24. PubMed ID: 24419495
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?
    Muttukrishna S; Suharjono H; McGarrigle H; Sathanandan M
    BJOG; 2004 Nov; 111(11):1248-53. PubMed ID: 15521870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.